Beat growth, margin pressure starts

The headline says Lupin crushed Q1—revenue up 32%, EBITDA a record ₹2,464 Cr. But read deeper and the story flips. Profit growth lagged revenue growth by half (16% PAT vs 32% sales). Net margins compressed 70 basis points. Management reiterated FY27 guidance unchanged—high single-digit growth, EBITDA ~25%—and explicitly walked the US business down to USD 250–280M per quarter starting Q2 due to Tolvaptan and Mirabegron competition. The quarter was the peak. Everything else is downhill.

Gross margin hit 74.6% in Q1, up 330 basis points from 71.3% prior year. Lupin attributed this to better product mix and volumes. But management flagged it as unsustainable. Q1 benefited from old inventory carried at lower cost; as that runs down, prices will flow through and input cost inflation (geopolitical tensions cited) will bite. Normalized gross margin expected to settle around 71%—a 360 basis point step-down from Q1's exceptional level. This is the margin compression story in miniature.

Guidance stayed flat—FY27 'high single-digit growth' reaffirmed, EBITDA 25% maintained—but the granularity shifted dramatically. Management moved from vague 'increased competition' language to explicit numbers: Tolvaptan entrants (Apotex, Teva, potentially a 3rd in September) and a quarterly US revenue guidance of USD 250–280M for Q2–Q4 (a 25% drop QoQ from Q1's USD 366M). Cost inflation (geopolitical tensions) was quantified for the first time: Q1 insulated by old inventory, but H2 will see margin pressure. Pipeline milestones also advanced: 50+ launches over 3 years (10 exclusive first-to-files, 5 biosimilars), Pegfilgrastim expected H2 FY27, Apixaban 505(b)(2) September approval target, Spiriva Respimat device filing this fiscal year.

Q1 US sales hit USD 366M, annualizing to roughly USD 1.47B. FY27 guidance sits at USD 1.1–1.2B. The gap is enormous—a 18–25% full-year step-down from Q1's run rate. This assumes sequential decline: management explicitly guided Q2–Q4 to USD 250–280M per quarter. The culprit: Tolvaptan (38% market share, specialty pharma + REMS moat, but facing Apotex and Teva from Q2) and Mirabegron (already under pressure in Q1, full competitive impact from Q2). Together, these two drugs are expected to see pricing erosion and share loss as a four-player market fragments. Analysts pressed hard; management held firm. The implication: US will not return to growth trajectory until FY28, when new launches (Pegfilgrastim biosimilar, respiratory complex generics, Apixaban 505(b)(2)) ramp.

EBITDA margin guidance sits at ~25% for FY27, down 460 basis points from Q1's 29.6%. The drivers are transparent: (1) Tolvaptan/Mirabegron competitive reallocation; (2) gross margin normalization from 74.6% to ~71%; (3) adjacency business losses (Diagnostics, Digital, OTC, CDMO collectively drag 1–1.5% EBITDA, expected to turn breakeven next year). R&D stays at 8% of sales (₹608 Cr in Q1, tracking to guidance), supporting respiratory, injectable, and biosimilar pipelines. Employee costs, however, inflated 28% YoY—a material headwind on absorption that likely persists if geopolitical tensions continue.

Price action: The stock opened down 0.9% on day 1 of the announcement, then steadily declined to -5.65% by day 5—a damning verdict on what should have been a beat. The market did not buy the 'peak quarter' narrative for long; it instead priced in the forward compression. Current price ₹2,235 is 11.64% below its all-time high and trades below its 20-day, 50-day, and 200-day simple moving averages. RSI at 22.3 signals oversold conditions, suggesting some technical bounce risk, but fundamental recovery requires daylight on US headwinds.

Ownership flows: Foreign institutional investors added 71 basis points of stake to 22.42% in Q1, a modest vote of confidence. Domestic institutions trimmed 67 basis points to 24.65%, a smaller but real pullback. Promoter stake stable at 46.85%. The FII nibble is not aggressive accumulation; DII's trim is a hedging signal. Together they suggest the street is waiting—not yet convicted, not yet fearful, but skeptical of near-term recovery.

Valuation context: At ₹2,235, Lupin trades 11.64% below its all-time high, a meaningful drawdown. Given that the ATH likely priced in higher FY27 guidance and earnings momentum, the current discount reflects the street's repricing of margin and US headwinds. It is not yet a deep-value opportunity—the stock has room to compress further if Q2 US revenue undershoots the USD 250–280M guidance or if margin consensus softens below 25%.